

Minneapolis VA Health Care System
IBC (Institutional Biosafety Committee)

MEETING MINUTES

December 19, 2023

Teams

The meeting was called to order on December 19, 2023 at 5:00 PM and a quorum was present.

ATTENDANCE

Voting Members Present:

██████████	Chair
██████████	Deputy Healthcare Epidemiologist
██████████	Community Member
██████████	Attending Veterinarian

Non-Voting Attendees, Staff and Guests Present:

██████████	IBC Coordinator
██████████	Incoming 2024 IBC Coordinator

Recording:

██████████	Incoming 2024 IBC Coordinator
------------	-------------------------------

ITEMS

1 Welcome and Opening Remarks

2 General Announcements

██████████ introduced ██████████ as the incoming IBC Coordinator for 2024 as ██████████ is retiring at the end of 2023.

3 Continuing Reviews

3.1 [██████████] Combinatorial Targeting of the Cell Cycle and Key Interacting Pathways in Mesothelioma

PI:	Mark Klein
Reference Number:	██████████
Sponsor:	VA-ORD Biomedical Laboratory Research & Development
Submission Type:	Continuing Review/Progress Report

Review Type: Full Committee Review
Action: Approved
Effective Date: December 19, 2023
Project Status: Active
Vote: Total = 4; For = 4; Opposed = 0; Abstained = 0;
Primary Reviewer: [REDACTED]

Discussion and Remarks:

In this study lentiviral vectors will be used to up- or down-regulate CDK2 (cyclin-dependent kinase 2) and TXN2 (thioredoxin 2) in mesothelioma cells in vitro. Lenti-ORF-CDK2 (open reading frame) and lenti-ORF-TXN2 for up-regulation and lenti-shRNA vectors for down-regulation will be obtained from OriGene. The lentiviral vector is a third-generation system that utilizes a heterologous coat protein in place of the HIV-1 envelope protein, vector and packaging functions in 4 different plasmids, and removal of the Tat gene necessary for replication. These factors greatly reduce the chance of replication competent lentivirus being produced. All personnel are current with completion of safety training. There were no changes to the experiments and they have been conducted as outlined with no adverse effects to personnel reported.

4 Closures

4.1 [REDACTED] Precision Oncology-Based Therapeutic Targeting in Mesothelioma

PI: Mark Klein
Reference Number: IACUC/SRS/IBC
Sponsor: Department of Defense
Submission Type: Closure/Final Report

Review Type: Full Committee Review
Action: Closed
Effective Date: December 19, 2023
Project Status: Closed
Vote: Total = 4; For = 4; Opposed = 0; Abstained = 0;
Primary Reviewer: [REDACTED]

Discussion and Remarks:

This project is closed. There is no longer any benchwork or sample storage.

[REDACTED] reviewed this submission and has no concerns, so recommends approval of its closure.

4.2 [REDACTED] Novel Plant Alkaloids for the Treatment of Obesity in Mice

PI: Patricia Bunney
Reference Number: [REDACTED]
Submission Type: Closure/Final Report

Review Type: Administrative Review

Action: Closed
Effective Date: December 19, 2023
Project Status: Closed
Vote: Total = 4; For = 4; Opposed = 0; Abstained = 0;

Discussion and Remarks:

This PI has left the Minneapolis VAHCS so the project is now administratively closed.

5 Adjourn

The meeting adjourned on December 21, 2023 at 5:14 PM.

